As of Apr 20
| -0.08 / -0.07%|
The 5 analysts offering 12-month price forecasts for Madrigal Pharmaceuticals Inc have a median target of 175.00, with a high estimate of 210.00 and a low estimate of 150.00. The median estimate represents a +47.16% increase from the last price of 118.92.
The current consensus among 6 polled investment analysts is to Buy stock in Madrigal Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.